GEn1E has a pipeline of programs with strong preclinical data. The p38 kinase inhibitors represent a platform for the treatment of various inflammatory and age-related diseases.

Screen Shot 2019-04-08 at 8.45.32 PM.png

P38 Kinase Inhibitor Program

The P38 kinase inhibitor is initially being developed for a rare disease with no current FDA approved treatments, Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS).  Appx. 150,000 to < 200,000 patients have ALI/ARDS in the USA. Costs per patient are appx. $50,000 - $100,000 due to high ICU and ventilator costs, thus making it an area of huge unmet medical need. The lead compounds show strong in vitro and preclinical efficacy in an acute lung injury model.


These novel, selective p38α kinase inhibitors address inflammatory and age-related diseases.

ALI/ARDS approval will be followed by approvals for inflammatory and age-related diseases.